pembrolizumab 200 mg (KEYTRUDA ®) clinical trials

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

This study looks at a new drug, S095029, combined with an existing treatment, pembrolizumab, for advanced stomach or gastroesophageal junction cancer. It aims to check safety and how well it works for specific types of cancer that have particular genetic markers.